Published in Cardiovascular Business Week, October 26th, 2004
This roster of international scientists will provide advice and direction on how GNI's capabilities in systems pharmacology and gene network generation can be applied to develop improved therapeutics for the treatment of inflammatory, cardiovascular, and infectious diseases and cancer.
"The board's formation is a key step towards executing our stated strategy," said Christopher Savoie, MD, PhD, chairman and CEO of GNI. "This focuses on using our expertise to develop drugs that are more effective and have fewer side effects. We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.